The City of Québec financially supports Pharma in silica

Québec City, February 3rd, 2020 — The staff and shareholders of Pharma in silica inc. express their gratitude to the City of Québec for its startup contribution of $250 000 via the Vision entrepreneuriale Program.

The Québec City company begun in March of 2019 the design of the in silica™ nanocarrier. The City of Québec contribution will consolidate the funds received from private investors, mainly from the Québec region, and the federal and provincial R&D tax credits, in order to propel this minuscule silica-made truck (150 billionths of a meter) toward its first destination : the most deadly of lung cancers.

« The launch of a life science endeavor is the most uncertain stage of the long journey toward the patient », declared Michel L'Heureux, MD, entrepreneur and member of the board. « The four private investors that subscribed 750 000$ in 2019 are well aware of this; they celebrate the tangible and valuable support provided by the City of Québec to Pharma in silica. »

Pharma in silica's hypothesis is that its silica spheres will increase the efficacy and reduce the toxicity of certain drugs, namely against cancer, inflammation and other pathologies.

« Québec pumps today 250 000 liters of fuel in our gas tank », appreciates François Arcand, the president of Pharma in silica. « Its 20 % of added mileage for 6,5 persons, including 5 chemistry PhDs, for assays with animals at Université Laval, for the canvassing of investors for our next step. Our municipality boosts by 20% the probability of success of Pharma in silica. In the life science world, this is immense. »

Pharma in silica intends to close a second equity financing during 2020 and to conduct its first preclinical assays at the beginning of 2021.

About Pharma in silica inc.

Laboratoires Pharma in silica inc. is a preclinical-stage pharmaceutical company based in Québec City's Parc Technologique. Since 2019, it has been developing novel treatments for solid cancers (lung, breast, etc.) using OpPacli™, a patented drug nanocarrier. The company is driven by a dynamic group of chemists, pharmacists and managers led by François Arcand, an experienced life sciences entrepreneur (Medicago, Conferences on Plant-made Pharmaceuticals, ERA Biotech). The company established its own research and production facilities and collaborates with oncology experts and world-renowned research centers and has completed the pre-IND/CTA meetings with the FDA and Health Canada.

For more information

François Arcand
President, Pharma in silica inc
514 994 1023 / 418 874-0054 #233
info@pharma-insilica.com

> all news